Compare Marvell Technology Inc (MRVL) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Health Care Select Sector SPDR Fund — how do they compare? Marvell Technology Inc trades at $275.28 (market cap $246.84B), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Marvell Technology Inc is far larger — about 5.7× Health Care Select Sector SPDR Fund's market cap, and Marvell Technology Inc pays a 0.09% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| MRVL | XLV | |
|---|---|---|
Market Cap | $246.84B | $43.48B |
Volume | 29,003,830 | 11,121,431 |
Sector | Technology | — |
52-Week High | $316.43 | $175.68 |
52-Week Low | $73.73 | $141.95 |
Typical Hold Time | 42 Days | 100 Days |
Enterprise Value | $248.19B | — |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day, but maintains strong analyst support with 84% buy ratings and a $327.86 consensus price target. The stock shows bullish technical signals with support at $267 and resistance at $282, while recent earnings beats and projected revenue growth to $9.5B in 2026 highlight fundamental momentum. Management's raised 2028 revenue guidance to $18B and major hyperscaler deals underscore the company's positioning in AI infrastructure.
Outlook remains positive driven by AI chip demand and custom silicon growth, though high valuations (P/E 90.95) and margin pressures present risks. The stock offers significant upside to analyst targets but requires monitoring of execution against aggressive growth forecasts and competitive dynamics in the semiconductor space.
XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.
XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
